Systemic juvenile xanthogranuloma: A systematic review
Pediatric Blood & Cancer · 2023-05 · 70 (5)
DOI: 10.1002/pbc.30232 ↗At a glance
Systematische Übersicht in Pediatric Blood & Cancer, published online on 2023-02-13. Written by Tong Zou and 10 co-authors. Institution: Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key L…. Major MEDLINE topics: Xanthogranuloma, Juvenile. Cited 35 times so far (Crossref); 19 references. Funded by: National Natural Science Foundation of China.
Abstract (original language)
Objective
To perform a systematic review to investigate the available literature regarding systemic juvenile xanthogranuloma (SJXG) and report the population characteristics, clinical manifestation, therapy, and outcome. Review methods A search of PubMed, Embase, and Cochrane Library for all articles published between 1981 and 2022 was performed with variations and combinations of the following search terms: extracutaneous, visceral, systemic, and juvenile xanthogranuloma (JXG). Data extracted included demographics, organ involvement, treatment, outcome, and permanent sequelae.
Results
A total of 103 articles encompassing 159 patients met the inclusion criteria. The median onset age was 9 months, with a male predominance (61%). The distribution of major involved organs varied by age, and younger onset age was associated with more organ involvement. The most commonly involved site was the central nervous system (CNS) (40.9%), followed by the liver (31.4%), the lung (18.9%), and the eye (18.2%). At the termination of follow‐up, 93 patients (58.5%) were alive with no disease, 56 (35.2%) were alive with disease, and 10 (6.3%) were dead of disease. There was a significant difference in outcome between patients with and without spleen involvement ( p = .0003), and patients with spleen involvement suffered a higher risk of death. Permanent sequelae mainly comprised CNS symptoms and ocular manifestations.
Conclusions
SJXG can involve varying numbers and combinations of extracutaneous sites. There is no standard therapy for SJXG and clinicians should choose individualized therapy modalities.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Disease in Children, Ministry of Education, Beijing…
- Center for Clinical Epidemiology and Evidence-based Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- Hematologic Disease Laboratory, Beijing Pediatric Research Institute, Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key L…
ORCID profiles: Tong Zou, Ang Wei, Yunze Zhao, Rui Zhang
Funding
- National Natural Science Foundation of China
Cite
APA
Zou, T., Wei, A., Ma, H., Lian, H., Liu, Y., Wang, D., Zhao, Y., Cui, L., Li, Z., Zhang, R., & Wang, T. (2023). Systemic juvenile xanthogranuloma: A systematic review. Pediatric Blood & Cancer, 70(5). https://doi.org/10.1002/pbc.30232
Vancouver
Zou T, Wei A, Ma H, Lian H, Liu Y, Wang D, et al. Systemic juvenile xanthogranuloma: A systematic review. Pediatric Blood & Cancer. 2023;70(5). doi:10.1002/pbc.30232
BibTeX
@article{Zou2023,
author = {Zou, Tong and Wei, Ang and Ma, Honghao and Lian, Hongyun and Liu, Yali and Wang, Dong and Zhao, Yunze and Cui, Lei and Li, Zhigang and Zhang, Rui and Wang, Tianyou},
title = {Systemic juvenile xanthogranuloma: A systematic review},
journal = {Pediatric Blood & Cancer},
year = {2023},
volume = {70},
number = {5},
doi = {10.1002/pbc.30232}
}
EUVIMED